Can Fluorodihydroxyphenylalanine PET Replace Somatostatin Receptor Scintigraphy in Patients with Digestive Endocrine Tumors?

Journal of Nuclear Medicine

Khaldoun Kerrou¹  Fabrice Gutman¹  Jean-Pierre Lotz¹  Françoise Montravers¹  Nicolas Aide¹  Philippe Ruszniewski¹  Jean-Noël Talbot¹  Virginie de Beco¹  Dany Grahek¹  Jean-Didier Grangé¹ 

关键词: ¹⁸F-FDOPA PET;    ¹¹¹In-pentetreotide somatostatin receptor scintigraphy;    well-differentiated digestive endocrine tumor;   

DOI  :  

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

The aim of this study was to evaluate whether 18F-fluorodihydroxyphenylalanine (18F-FDOPA) PET is accurate for the diagnosis and follow-up of any type of well-differentiated digestive endocrine tumor and to assess its performance compared with standard somatostatin receptor scintigraphy (SRS) using 111In-pentetreotide. Methods: We reviewed the results of 33 evaluable 18F-FDOPA PET and 111In-pentetreotide SRS examinations performed between March 2002 and September 2005 in 30 patients referred for documented well-differentiated digestive endocrine tumor. Results: The sensitivity and accuracy of 18F-FDOPA PET were significantly better for carcinoid tumors (defined according to the World Health Organization 2000 classification) (n = 19) than for noncarcinoid tumors (n = 14)that is, 93% versus 25% for sensitivity (P < 0.01) and 89% versus 36% for accuracy (P < 0.01), respectively. In contrast, the performances of 111In-pentetreotide SRS did not differ according to the carcinoid or noncarcinoid type of the primary endocrine tumorthat is, 81% versus 75% for sensitivity and 79% versus 71% for accuracy, respectively. In carcinoid tumors, comparison between 18F-FDOPA PET and 111In-pentetreotide SRS showed that 18F-FDOPA PET more accurately evaluated the extent of disease than 111In-pentetreotide SRS. 111In-Pentetreotide SRS did not reveal any additional lesions in any case. Conversely, in noncarcinoid tumors, the extent of the disease was more accurately evaluated in all cases by 111In-pentetreotide SRS than by 18F-FDOPA PET. Conclusion: This preliminary study emphasizes the importance of a precise histologic characterization of well-differentiated digestive endocrine tumor to select the best radiopharmaceutical. 18F-FDOPA PET appears to be useful in carcinoid tumors and could become the first-line scintigraphic imaging modality for these tumors, but 111In-pentetreotide SRS appeared to be a better first-line scintigraphic imaging modality for noncarcinoid digestive tumors.

【 授权许可】

Unknown